Coherus Neulasta biosimilar loses preferred status at Express Scripts

Coherus BioSciences (CHRS -2.6%) slips on below-average volume in apparent reaction to the exclusion of Udencya (pegfilgrastim-cbqv), a biosimilar to Amgen’s (AMGN -0.8%) Neulasta, from Express Scripts’ 2021 preferred formulary that goes into effect January 1.

The pharmacy benefit manager’s preferred Neulasta biosimilars for next year are Mylan’s (MYL -0.9%) Fulphila (pegfilgrastim-jmdb) and Novartis’ (NVS +1.9%) Ziextenzo (pegfilgrastim-sndz).

https://seekingalpha.com/news/3607625-coherus-neulasta-biosimilar-loses-preferred-status-express-scripts